Survival and prognostic factors of pulmonary oligometastases treated with stereotactic body radiotherapy
Background: Stereotactic body radiotherapy (SBRT) for pulmonary oligometastatic disease
achieves excellent treatment outcomes in terms of local control and toxicity. Patients treated …
achieves excellent treatment outcomes in terms of local control and toxicity. Patients treated …
Local ablative therapies in oligometastatic NSCLC: New data and new directions
The oligometastatic and oligoprogressive disease states have been recently recognized as
common clinical scenarios in the management of non-small cell lung cancer (NSCLC). As a …
common clinical scenarios in the management of non-small cell lung cancer (NSCLC). As a …
[HTML][HTML] Oligometastatic non-small cell lung cancer: is there a role for locoregional therapy?
L Berzenji, PE Van Schil - Journal of Thoracic Disease, 2017 - ncbi.nlm.nih.gov
© Journal of Thoracic Disease. All rights reserved. J Thorac Dis 2017; 9 (7): 1814-1817 jtd.
amegroups. com therapy as initial treatment (11). None of the patients had evidence of …
amegroups. com therapy as initial treatment (11). None of the patients had evidence of …
[HTML][HTML] Patients with colorectal lung oligometastases (L-OMD) treated by dose adapted SABR at diagnosis of oligometastatic disease have better outcomes than …
A Mihai, Y Mu, J Armstrong, M Dunne… - … of Radiosurgery and …, 2017 - ncbi.nlm.nih.gov
Aim To evaluate the clinical outcomes of patients with OMD from a CRC primary, who
underwent SABR either as first treatment at diagnosis of metachronous oligometastatic …
underwent SABR either as first treatment at diagnosis of metachronous oligometastatic …
Radiotherapy in the management of synchronous metastatic lung cancer
J Khalifa, A Lévy, LM Sauvage, S Thureau… - Cancer …, 2024 - Elsevier
Metastatic lung cancer classically portends a poor prognosis. The management of metastatic
lung cancer has dramatically changed with the emergence of immune checkpoint inhibitors …
lung cancer has dramatically changed with the emergence of immune checkpoint inhibitors …
[PDF][PDF] Oligometastases: the new paradigm and options for radiotherapy
H Badakhshi, A Grün, C Stromberger… - A critical review …, 2013 - academia.edu
A new paradigm is increasingly determining clinical practice: the oligometastatic state.
Radiotherapy plays an important role here, as one of the main therapeutic oncological …
Radiotherapy plays an important role here, as one of the main therapeutic oncological …
[HTML][HTML] Oligometastatic Non–Small-Cell Lung Cancer: How Should We Define and Manage It?
DE Gerber - Journal of oncology practice, 2018 - ncbi.nlm.nih.gov
Recent years have seen a markedly increased interest in the concept of oligometastatic
disease in non–small-cell lung cancer (NSCLC). Lacking a precise and consistent definition …
disease in non–small-cell lung cancer (NSCLC). Lacking a precise and consistent definition …
Is it time for redefining oligometastatic disease? Analysis of lung metastases CT in ten tumor types
ON Gofrit, B Gofrit, Y Roditi, A Popovtzer, S Frank… - Discover Oncology, 2023 - Springer
Background Oligometastatic disease (OD) is usually defined arbitrarily as a condition in
which there are≤ 5 metastases. Given limited disease, it is expected that patients with OD …
which there are≤ 5 metastases. Given limited disease, it is expected that patients with OD …
Prognosis of non-small cell lung cancer patients with bone oligometastases treated concurrently with thoracic three-dimensional radiotherapy and chemotherapy
WW Ouyang, SF Su, Z Ma, YX Hu, B Lu, QS Li… - Radiation …, 2014 - Springer
Background To evaluate the efficacy of three-dimensional radiotherapy for non-small cell
lung cancer (NSCLC) patients with bone metastases. Methods Clinical data for 95 NSCLC …
lung cancer (NSCLC) patients with bone metastases. Methods Clinical data for 95 NSCLC …
[HTML][HTML] Stereotactic body radiotherapy as an alternative to metastasectomy for pulmonary oligometastasis
Y Matsuo - Journal of Thoracic Disease, 2019 - ncbi.nlm.nih.gov
© Journal of Thoracic Disease. All rights reserved. J Thorac Dis 2019; 11 (Suppl 9): S1420-
S1422| http://dx. doi. org/10.21037/jtd. 2019.02. 94 20% and 57% of the PM and SBRT …
S1422| http://dx. doi. org/10.21037/jtd. 2019.02. 94 20% and 57% of the PM and SBRT …